This is a monocentric, low-risk interventional study designed to characterize established treatment-related dermatologic toxicity in patients receiving systemic anticancer therapies. The study will not modify or influence oncologic treatment decisions but will perform standardized instrumental and clinical dermatologic assessments during the course of routine cancer care.
Adults aged 18 years and older.
Taxanes (e.g., paclitaxel, docetaxel) breast cancer or ovarian cancer.
Neoadjuvant Pembrolizumab for stage III NSCLC
Ipilimumab + nivolumab neoadjuvant for stage III and first-line metastatic treatment for patients with PD-L1 < 1% or asymptomatic brain metastases, or after progression on BRAF and MEK inhibitors in melanoma.
Pre-existing chronic dermatologic disease likely to confound assessment of treatment-related toxicity (e.g., psoriasis, atopic dermatitis/eczema, lupus, chronic urticaria), unless clinically inactive and deemed non-confounding by the investigator/dermatologist.
Active skin infection at the assessment site (bacterial, viral, fungal) that may alter barrier measures.
Any medical or dermatologic condition that, in the investigator's judgment, may confound assessment of treatment-related skin toxicity.
Single group
skin barrier assessment
Diagnostic testAssessment of skin barrier integrity, quantified by transepidermal water loss (TEWL) measured under standardized conditions
transepidermal water loss (TEWL)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
